Tamar C. Brandler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tamar C. Brandler has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Aylin Simsir
Department of Pathology New York University Langone Health New York New York USA
17 shared publicationsWei Sun
Department of Pathology New York University Langone Health New York New York USA
17 shared publications- Fang Zhou
Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, NY
11 shared publications - Margaret Cho
Department of Pathology, New York University Langone Medical Center, New York, New York
6 shared publications Xiao‐Jun Wei
Department of Pathology, New York University School of Medicine, New York, New York
6 shared publicationsFang Zhou
Department of Pathology New York University Langone Health New York New York USA
5 shared publications
Latest Publications
- 9 April 2026
- Published by Wiley in Cancer Cytopathology
- Vol. 134 (5) , e70093
Utility of ACR TI‐RADS to determine need for repeat FNA in thyroid nodules with nondiagnostic cytology
Background: Nondiagnostic cytology for thyroid nodules, consistent with The Bethesda System for Reporting Thyroid Cytopathology category I (B1) poses a management dilemma for clinicians. The objective of this study was to define the malignancy risk of nodules with B1 cytology using American College of Radiology Thyroid Imaging Reporting & Data System (TI‐RADS) and to assess whether TI‐RADS can help guide the decision to perform a repeat biopsy of these nodules. Materials and methods: This retrospective cohort study evaluated 139 B1 nodules that had a definitive diagnosis on repeat biopsy or surgical excision. Sonographic features were evaluated and classified according to TI‐RADS. TI‐RADS category and total points were compared to the final diagnosis to determine the malignancy risk of B1 thyroid nodules. Results: Of the 139 nodules, 11 (7.9%) were malignant. The malignancy risk of nodules assigned TI‐RADS category 1 and 2 were both 0%, TI‐RADS 3 was 2.9%, whereas TI‐RADS 4 and 5 were 5.9% and 46.2%, respectively. The optimal cutoff for TI‐RADS points predicting malignancy was 5 points. Conclusion: B1 thyroid nodules in TI‐RADS categories 1–3 may not require repeat biopsy given low malignancy risk. However, B1 nodules in TI‐RADS categories 4 and 5 have a higher malignancy risk and thus should undergo repeat biopsy.
- 9 April 2026
- Published by Wiley in Cancer Cytopathology
- Vol. 134 (5) , e70093
Utility of ACR TI‐RADS to determine need for repeat FNA in thyroid nodules with nondiagnostic cytology
Background: Nondiagnostic cytology for thyroid nodules, consistent with The Bethesda System for Reporting Thyroid Cytopathology category I (B1) poses a management dilemma for clinicians. The objective of this study was to define the malignancy risk of nodules with B1 cytology using American College of Radiology Thyroid Imaging Reporting & Data System (TI‐RADS) and to assess whether TI‐RADS can help guide the decision to perform a repeat biopsy of these nodules. Materials and methods: This retrospective cohort study evaluated 139 B1 nodules that had a definitive diagnosis on repeat biopsy or surgical excision. Sonographic features were evaluated and classified according to TI‐RADS. TI‐RADS category and total points were compared to the final diagnosis to determine the malignancy risk of B1 thyroid nodules. Results: Of the 139 nodules, 11 (7.9%) were malignant. The malignancy risk of nodules assigned TI‐RADS category 1 and 2 were both 0%, TI‐RADS 3 was 2.9%, whereas TI‐RADS 4 and 5 were 5.9% and 46.2%, respectively. The optimal cutoff for TI‐RADS points predicting malignancy was 5 points. Conclusion: B1 thyroid nodules in TI‐RADS categories 1–3 may not require repeat biopsy given low malignancy risk. However, B1 nodules in TI‐RADS categories 4 and 5 have a higher malignancy risk and thus should undergo repeat biopsy.
- 12 September 2025
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (10) , e70045
DICER1 mutations in Bethesda III/IV thyroid cytology samples: A multicenter observational study
Background: Mutations in DICER1 are uncommon, poorly understood, and infrequently found in thyroid nodules.Methods: The objective of this study was to investigate category III/IV thyroid nodules according to The Bethesda System for Reporting Thyroid Cytopathology with DICER1 gene mutations detected in fine‐needle aspiration cytology samples using ThyroSeq v3 molecular testing, with a focus on an exploration of the clinical and histopathologic outcomes of these nodules. In this multicenter study spanning more than 6 years, nodules were retrospectively analyzed for patient demographics, clinical course, cytologic features, and histopathology, where available.Results: In total, 88 patients with somatic DICER1 mutations were included, with a mean age of 39.6 years and a female predominance. All mutations were in the somatic hotspot region, most commonly at the codon 5437 site. Most excised nodules showed benign histologic features (65.9%). Interestingly, the rate of malignancy was higher in this cohort compared with that in the national average.Conclusions: DICER1 mutations appear to confer a higher risk of malignancy, but are not associated with any specific cytological or histopathological distinguishing features.
- 12 September 2025
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (10) , e70045
DICER1 mutations in Bethesda III/IV thyroid cytology samples: A multicenter observational study
Background: Mutations in DICER1 are uncommon, poorly understood, and infrequently found in thyroid nodules.Methods: The objective of this study was to investigate category III/IV thyroid nodules according to The Bethesda System for Reporting Thyroid Cytopathology with DICER1 gene mutations detected in fine‐needle aspiration cytology samples using ThyroSeq v3 molecular testing, with a focus on an exploration of the clinical and histopathologic outcomes of these nodules. In this multicenter study spanning more than 6 years, nodules were retrospectively analyzed for patient demographics, clinical course, cytologic features, and histopathology, where available.Results: In total, 88 patients with somatic DICER1 mutations were included, with a mean age of 39.6 years and a female predominance. All mutations were in the somatic hotspot region, most commonly at the codon 5437 site. Most excised nodules showed benign histologic features (65.9%). Interestingly, the rate of malignancy was higher in this cohort compared with that in the national average.Conclusions: DICER1 mutations appear to confer a higher risk of malignancy, but are not associated with any specific cytological or histopathological distinguishing features.
- 20 August 2024
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (12) , 756-762
Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) (Milan IVB) and Its Subgroups: A Multi‐Institutional Analysis of Risk of Neoplasm and Malignancy
Objectives: Fine needle aspiration (FNA) plays a crucial role in their initial assessment of salivary gland neoplasms. In the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC), the category of Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) categorizes lesions with ambiguous features. This study aims to investigate the risk of neoplasm (RON) and risk of malignancy (ROM) within different subgroups of SUMP lesions using data from three large academic institutions.Methods: We analyzed salivary gland (FNA) cases from three academic institutions post‐MSRSGC implementation. Salivary gland FNA cases categorized as Milan IVB (SUMP) with subsequent surgical pathology follow‐up were analyzed. Cases were divided into basaloid, oncocytic, and clear cell SUMP subtypes, with RON and ROM assessed and compared.Results: Out of 1377 MSRSGC cases, 231 were SUMP (16.8%), with 101 subjected to surgical pathology follow‐up. The overall ROM for SUMP was 20.8%, with variations of 10% to 29.5% observed amongst institutions, but no significant difference was observed among three institutions (p = 0.15). Basaloid and oncocytic SUMP displayed 17.1% and 20.5% ROM, respectively, without significant disparity. However, all clear cell SUMP cases were malignant on surgical resection.Conclusions: This study highlights the variability in ROM for SUMP lesions and the significantly higher ROM in SUMP cases with clear cell features. These findings emphasize the importance of accurately subcategorizing SUMP lesions, particularly those with clear cell features, for appropriate clinical management.
- 20 August 2024
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (12) , 756-762
Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) (Milan IVB) and Its Subgroups: A Multi‐Institutional Analysis of Risk of Neoplasm and Malignancy
Objectives: Fine needle aspiration (FNA) plays a crucial role in their initial assessment of salivary gland neoplasms. In the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC), the category of Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) categorizes lesions with ambiguous features. This study aims to investigate the risk of neoplasm (RON) and risk of malignancy (ROM) within different subgroups of SUMP lesions using data from three large academic institutions.Methods: We analyzed salivary gland (FNA) cases from three academic institutions post‐MSRSGC implementation. Salivary gland FNA cases categorized as Milan IVB (SUMP) with subsequent surgical pathology follow‐up were analyzed. Cases were divided into basaloid, oncocytic, and clear cell SUMP subtypes, with RON and ROM assessed and compared.Results: Out of 1377 MSRSGC cases, 231 were SUMP (16.8%), with 101 subjected to surgical pathology follow‐up. The overall ROM for SUMP was 20.8%, with variations of 10% to 29.5% observed amongst institutions, but no significant difference was observed among three institutions (p = 0.15). Basaloid and oncocytic SUMP displayed 17.1% and 20.5% ROM, respectively, without significant disparity. However, all clear cell SUMP cases were malignant on surgical resection.Conclusions: This study highlights the variability in ROM for SUMP lesions and the significantly higher ROM in SUMP cases with clear cell features. These findings emphasize the importance of accurately subcategorizing SUMP lesions, particularly those with clear cell features, for appropriate clinical management.
- Open Access
- 4 October 2023
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 12 (5) , S60
RAS-mutated Thyroid Modules are a Mixed Bag- Can ThyraMIR Detect the Malignant Cases
- 4 October 2023
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 12 (5) , S60
Open AccessRAS-mutated Thyroid Modules are a Mixed Bag- Can ThyraMIR Detect the Malignant Cases
- 1 June 2023
- Published by SAGE Publications in Thyroid®
- Vol. 33 (6) , 715-723
Molecular Profiles of Noninvasive, Minimally Invasive, and Invasive Follicular Patterned Thyroid Neoplasms with Papillary Nuclear Features
Background: An increasing amount of data are being published which risk-stratify thyroid tumors according to genetic signatures and histologic morphology. Typically, follicular patterned lesions have been shown to harbor RAS-like mutations with more indolent behaviors. Our study aims to examine the extent of similarity amongst three groups of follicular patterned lesions with papillary nuclear features--noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) with capsular and/or angioinvasion and infiltrative follicular variant of papillary thyroid carcinoma (iFVPTC)--in order to help clarify whether NIFTP and EFVPTC represent a histologic continuum and the degree to which the genomic landscape further separates higher risk follicular patterned tumors like iFVPTC from more indolent ones (EFVPTC and NIFTP). Methods: ThyroSeq test results were compared for cases with histologic NIFTP, EFVPTC and iFVPTC in this retrospective study. Genetic drivers were subcategorized by level of aggressiveness. Gene expression alterations (GEAs) and copy number alterations (CNAs) were compared amongst the three histologic groups. Results: NIFTP and EFVPTC cases displayed predominantly RAS-like alterations (100% and 75% respectively) and RAS-like GEAs (55.2% and 47.2%), and many showed CNAs with 22q-loss. Despite a predominance of RAS-like alterations, EFVPTC cases showed molecular heterogeneity with significantly more intermediate and aggressive drivers (22.3% of cases) than NIFTP (0%), p= 0.0068. iFVPTC cases displayed molecular profiles in between that of traditional follicular patterned lesions and classical papillary thyroid carcinoma, predominantly displaying intermediate and aggressive drivers (61.6%), which was significantly higher than that of EFVPTC (22.3%, p=0.0158) and NIFTP (0%, p<0.0001), illustrating the higher MAP-Kinase activity of iFVPTC. There was no significant difference however in comparing GEAs amongst the three histologic groups. Conclusions: While follicular patterned lesions with papillary nuclear features overall tend to display RAS-like alterations, EFVPTC cases, followed by iFVPTC in this series showed increasing proportions of more aggressive drivers. EFVPTC and NIFTP show much molecular overlap, with predominance of RAS-like alterations, suggesting that these tumors are part of a genetic continuum, while still ranked differentially. Preoperative molecular testing can potentially distinguish EFVPTC and iFVTPC from NIFTP based on a particular molecular signature, optimizing patient management.
- 1 June 2023
- Published by SAGE Publications in Thyroid®
- Vol. 33 (6) , 715-723
Molecular Profiles of Noninvasive, Minimally Invasive, and Invasive Follicular Patterned Thyroid Neoplasms with Papillary Nuclear Features
Background: An increasing amount of data are being published which risk-stratify thyroid tumors according to genetic signatures and histologic morphology. Typically, follicular patterned lesions have been shown to harbor RAS-like mutations with more indolent behaviors. Our study aims to examine the extent of similarity amongst three groups of follicular patterned lesions with papillary nuclear features--noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) with capsular and/or angioinvasion and infiltrative follicular variant of papillary thyroid carcinoma (iFVPTC)--in order to help clarify whether NIFTP and EFVPTC represent a histologic continuum and the degree to which the genomic landscape further separates higher risk follicular patterned tumors like iFVPTC from more indolent ones (EFVPTC and NIFTP). Methods: ThyroSeq test results were compared for cases with histologic NIFTP, EFVPTC and iFVPTC in this retrospective study. Genetic drivers were subcategorized by level of aggressiveness. Gene expression alterations (GEAs) and copy number alterations (CNAs) were compared amongst the three histologic groups. Results: NIFTP and EFVPTC cases displayed predominantly RAS-like alterations (100% and 75% respectively) and RAS-like GEAs (55.2% and 47.2%), and many showed CNAs with 22q-loss. Despite a predominance of RAS-like alterations, EFVPTC cases showed molecular heterogeneity with significantly more intermediate and aggressive drivers (22.3% of cases) than NIFTP (0%), p= 0.0068. iFVPTC cases displayed molecular profiles in between that of traditional follicular patterned lesions and classical papillary thyroid carcinoma, predominantly displaying intermediate and aggressive drivers (61.6%), which was significantly higher than that of EFVPTC (22.3%, p=0.0158) and NIFTP (0%, p<0.0001), illustrating the higher MAP-Kinase activity of iFVPTC. There was no significant difference however in comparing GEAs amongst the three histologic groups. Conclusions: While follicular patterned lesions with papillary nuclear features overall tend to display RAS-like alterations, EFVPTC cases, followed by iFVPTC in this series showed increasing proportions of more aggressive drivers. EFVPTC and NIFTP show much molecular overlap, with predominance of RAS-like alterations, suggesting that these tumors are part of a genetic continuum, while still ranked differentially. Preoperative molecular testing can potentially distinguish EFVPTC and iFVTPC from NIFTP based on a particular molecular signature, optimizing patient management.
- 3 May 2023
- Published by Elsevier in Seminars in Diagnostic Pathology
- Vol. 40 (5) , 349-352
Indeterminate Thyroid Nodules and Advances in Molecular Pathology
- 3 May 2023
- Published by Elsevier in Seminars in Diagnostic Pathology
- Vol. 40 (5) , 349-352
Indeterminate Thyroid Nodules and Advances in Molecular Pathology
- 19 August 2022
- Published by Wiley in Diagnostic Cytopathology
- Vol. 50 (12) , E386-E389
Liver fluke eggs in bile duct brush cytology: An unexpected diagnosis during evaluation of a biliary stricture
Clonorchis sinensis, a liver fluke parasite, infects humans through ingestion of raw or undercooked fish, crabs, or crayfish in endemic areas where the parasite is found. Clonorchis sinensis infects the liver, gallbladder, and bile duct in humans, causing Clonorichiasis. Although the majority of patients are asymptomatic, long-lasting infections may cause severe disease. Without treatment, human infection may persist for the parasite's lifespan (25-30 years). Pathologic diagnosis can be challenging as sampling may demonstrate limited cellularity with minuscule eggs that may be overlooked. Here, we report a rare case of liver fluke eggs diagnosed in bile duct brush cytology.
- 19 August 2022
- Published by Wiley in Diagnostic Cytopathology
- Vol. 50 (12) , E386-E389
Liver fluke eggs in bile duct brush cytology: An unexpected diagnosis during evaluation of a biliary stricture
Clonorchis sinensis, a liver fluke parasite, infects humans through ingestion of raw or undercooked fish, crabs, or crayfish in endemic areas where the parasite is found. Clonorchis sinensis infects the liver, gallbladder, and bile duct in humans, causing Clonorichiasis. Although the majority of patients are asymptomatic, long-lasting infections may cause severe disease. Without treatment, human infection may persist for the parasite's lifespan (25-30 years). Pathologic diagnosis can be challenging as sampling may demonstrate limited cellularity with minuscule eggs that may be overlooked. Here, we report a rare case of liver fluke eggs diagnosed in bile duct brush cytology.
- 16 July 2022
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 158 (5) , 583-597
The Milan System for Reporting Salivary Gland Cytopathology
Objectives: Our study assesses whether the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) offers any benefit over the original cytology classification, and measures interobserver agreement.Methods: Four cytopathologists retrospectively blindly classified preoperative cytology by MSRSGC from 101 resected salivary tumors. Consensus MSRSGC diagnoses were correlated with surgical pathology diagnoses and compared with the original cytology classification. Diagnostic parameters were calculated for both systems. Interobserver variability was assessed.Results: The original cytology classification vs MSRSGC had sensitivity, specificity, positive predictive value, and negative predictive value of 75.0% vs 78.3%, 97.1% vs 98.0%, 91.2% vs 94.7%, and 90.1% vs 90.0%, respectively. The original cytology classification risk of neoplasm (RON) was 91.7% for “negative for malignancy” and 100.0% for other categories. The MSRSGC RON was 71.4% in category II (nonneoplastic) and 100.0% in all other categories. The original cytology classification risk of malignancy (ROM) ranged from 0.0% for “atypical” to 100.0% for “positive for malignancy.” The MSRSGC ROM ranged from 0.0% in categories I (nondiagnostic) and III (nonneoplastic) to 100.0% in category VI (malignant). Weighted agreement using the MSRSGC was 92% (Gwet AC1, 0.84); unweighted agreement was 69% (Gwet AC1, 0.64). MSRSGC category IVA (benign neoplasm) was most likely to show interobserver agreement, with complete agreement in 67% of cases.Conclusions: The MSRSGC performs similarly to the original cytology classification and shows relatively high interobserver agreement.
- 16 July 2022
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 158 (5) , 583-597
The Milan System for Reporting Salivary Gland Cytopathology
Objectives: Our study assesses whether the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) offers any benefit over the original cytology classification, and measures interobserver agreement.Methods: Four cytopathologists retrospectively blindly classified preoperative cytology by MSRSGC from 101 resected salivary tumors. Consensus MSRSGC diagnoses were correlated with surgical pathology diagnoses and compared with the original cytology classification. Diagnostic parameters were calculated for both systems. Interobserver variability was assessed.Results: The original cytology classification vs MSRSGC had sensitivity, specificity, positive predictive value, and negative predictive value of 75.0% vs 78.3%, 97.1% vs 98.0%, 91.2% vs 94.7%, and 90.1% vs 90.0%, respectively. The original cytology classification risk of neoplasm (RON) was 91.7% for “negative for malignancy” and 100.0% for other categories. The MSRSGC RON was 71.4% in category II (nonneoplastic) and 100.0% in all other categories. The original cytology classification risk of malignancy (ROM) ranged from 0.0% for “atypical” to 100.0% for “positive for malignancy.” The MSRSGC ROM ranged from 0.0% in categories I (nondiagnostic) and III (nonneoplastic) to 100.0% in category VI (malignant). Weighted agreement using the MSRSGC was 92% (Gwet AC1, 0.84); unweighted agreement was 69% (Gwet AC1, 0.64). MSRSGC category IVA (benign neoplasm) was most likely to show interobserver agreement, with complete agreement in 67% of cases.Conclusions: The MSRSGC performs similarly to the original cytology classification and shows relatively high interobserver agreement.
- Open Access
- 1 July 2022
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 41 (3) , 480-492
Do ACR TI-RADS scores demonstrate unique thyroid molecular profiles?
Purpose: The present study aimed to examine the molecular profiles of cytologically indeterminate thyroid nodules stratified by American College of Radiology Thyroid Imaging Reporting and Data System (TI-RADS) categories and to determine whether certain ultrasonographic features display particular molecular alterations.Methods: A retrospective review was conducted of cases from January 1, 2016 to April 1, 2018. Cases with in-house ultrasonography, fine-needle aspiration Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) diagnoses, molecular testing, and surgery were included. All cases were diagnosed as TBSRTC indeterminate categories. The ultrasound studies were retrospectively reviewed and assigned TI-RADS scores (TR1-TR5) by board-certified radiologists. The final diagnoses were determined based on the surgical resection pathology. Binary logistic regression analysis was used to study whether demographic characteristics, TI-RADS levels, and TBSRTC diagnoses were associated with ThyroSeq molecular results.Results: Eighty-one cases met the inclusion criteria. RAS mutations were the most common alteration across all TI-RADS categories (TR2 2/2; TR3 10/19, TR4 13/44, and TR5 8/16), and did not stratify with any particular TI-RADS category. Only TR4 and TR5 categories displayed more aggressive mutations such as BRAFV600E and TERT. ThyroSeq results were positively correlated with thyroid malignancy when non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was categorized in the malignant category (odds ratio [OR], 6.859; P<0.01), but not when NIFTP was removed from the malignancy category. Echogenicity scores were found to be negatively correlated with ThyroSeq results in thyroid nodules (OR, 0.162; P<0.01).Conclusion: Higher-risk molecular alterations tended to stratify with the higher TI-RADS categories.
- 1 July 2022
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 41 (3) , 480-492
Open AccessDo ACR TI-RADS scores demonstrate unique thyroid molecular profiles?
Purpose: The present study aimed to examine the molecular profiles of cytologically indeterminate thyroid nodules stratified by American College of Radiology Thyroid Imaging Reporting and Data System (TI-RADS) categories and to determine whether certain ultrasonographic features display particular molecular alterations.Methods: A retrospective review was conducted of cases from January 1, 2016 to April 1, 2018. Cases with in-house ultrasonography, fine-needle aspiration Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) diagnoses, molecular testing, and surgery were included. All cases were diagnosed as TBSRTC indeterminate categories. The ultrasound studies were retrospectively reviewed and assigned TI-RADS scores (TR1-TR5) by board-certified radiologists. The final diagnoses were determined based on the surgical resection pathology. Binary logistic regression analysis was used to study whether demographic characteristics, TI-RADS levels, and TBSRTC diagnoses were associated with ThyroSeq molecular results.Results: Eighty-one cases met the inclusion criteria. RAS mutations were the most common alteration across all TI-RADS categories (TR2 2/2; TR3 10/19, TR4 13/44, and TR5 8/16), and did not stratify with any particular TI-RADS category. Only TR4 and TR5 categories displayed more aggressive mutations such as BRAFV600E and TERT. ThyroSeq results were positively correlated with thyroid malignancy when non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was categorized in the malignant category (odds ratio [OR], 6.859; P<0.01), but not when NIFTP was removed from the malignancy category. Echogenicity scores were found to be negatively correlated with ThyroSeq results in thyroid nodules (OR, 0.162; P<0.01).Conclusion: Higher-risk molecular alterations tended to stratify with the higher TI-RADS categories.